Funding sources This was an investigator-initiated study. The Radboud University Nijmegen Medical Centre was supported in part by UMC St Radboud Foundation, who received funding from Wyeth Pharmaceuticals for the project. Wyeth Pharmaceuticals played no role in the design and conduct of the study, data collection, data management, data analysis, interpretation of the data, manuscript preparation, manuscript review or manuscript approval.
Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab
Article first published online: 20 JUL 2011
© 2011 The Authors. BJD © 2011 British Association of Dermatologists 2011
British Journal of Dermatology
Volume 165, Issue 2, pages 375–382, August 2011
How to Cite
van Lümig, P.P.M., Driessen, R.J.B., Roelofs-Thijssen, M.A.M.A., Boezeman, J.B.M., van de Kerkhof, P.C.M. and de Jong, E.M.G.J. (2011), Relevance of laboratory investigations in monitoring patients with psoriasis on etanercept or adalimumab. British Journal of Dermatology, 165: 375–382. doi: 10.1111/j.1365-2133.2011.10329.x
Conflicts of interest These are listed in Appendix 1.
- Issue published online: 20 JUL 2011
- Article first published online: 20 JUL 2011
- Accepted manuscript online: 24 MAR 2011 12:35AM EST
- Accepted for publication 15 March 2011
This article has been cited by:
- 1Saudi practical guidelines on biologic treatment of psoriasis, Journal of Dermatological Treatment, 2014, 1, , , , , , , , , , , ,
- You have free access to this content2